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1. Introduction 
High density lipoprotein (HDL) is a macromolecular complex of proteins and lipids that is 
produced primarily by the liver through a complex pathway that requires initially the 
functions of apolipoprotein A-I (apoA-I), ATP binding cassette transporter A1 (ABCA1) 
and lecithin:cholesterol acetyl transferase (LCAT) (Zannis et al., 2006b). Following 
synthesis, HDL affects the functions of the arterial wall cells through signaling 
mechanisms mediated by scavenger receptor class B type-I (SR-BI) and other cell surface 
proteins. The impetus for studying HDL has been the inverse correlation that exists 
between plasma HDL levels and the risk for coronary artery disease (CAD) (Gordon et al., 
1989). HDL promotes cholesterol efflux (Gu et al., 2000; Nakamura et al., 2004), prevents 
oxidation of low density lipoprotein (LDL) (Navab et al., 2000a; Navab et al., 2000b), 
inhibits expression of proinflammatory cytokines by macrophages (Okura et al., 2010) as 
well as expression of adhesion molecules by endothelial cells (Cockerill et al., 1995; 
Nicholls et al,. 2005b). HDL inhibits cell apoptosis (Nofer et al., 2001) and promotes 
endothelial cell proliferation and migration (Seetharam et al., 2006). HDL stimulates 
release of nitric oxide (NO) from endothelial cells thus promoting vasodilation (Mineo et 
al., 2003). HDL also inhibits platelet aggregation and thrombosis (Dole et al., 2008) and 
has antibacterial, antiparasitic and antiviral activities (Parker et al., 1995; Singh et al., 1999; 
Vanhollebeke and Pays, 2010). Due to these properties HDL is thought to protect the 
endothelium and inhibit several steps in the cascade of events that lead to the 
pathogenesis of atherosclerosis and various other human diseases.  
This review focuses on two important aspects of contemporary HDL research. The first 
part considers briefly the structure of apoA-I and HDL and the key proteins that 
participate in the pathway of the biogenesis of HDL as well as clinical phenotypes 
associated with HDL abnormalities. The second part considers various physiological 
functions of HDL and apoA-I and the protective role of HDL against atherosclerosis and 
other diseases.  
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2. Biogenesis of HDL  
HDL is synthesized through a complex pathway (Zannis et al., 2004a). The first step 
involves an ABCA1 mediated transfer of cellular phospholipids and cholesterol to lipid poor 
apoA-I extracellularly. The lipidated apoA-I is gradually converted to discoidal particles 
that are remodelled in the plasma compartment by the esterification of cholesterol by the 
enzyme LCAT (Zannis et al., 2006a) and are converted to spherical HDL particles. The 
cholesteryl esters formed are transferred to very low-density lipoproteins/intermediate-
density lipoproteins/low density lipoproteins (VLDL/IDL/LDL) by the cholesteryl ester 
transfer protein (CETP) (Barter et al., 2003). Additional remodelling of HDL involves 
transfer of phospholipids from VLDL/LDL to HDL by the phospholipid transfer protein 
(PLTP) (Lusa et al., 1996), cholesterol efflux from cells or delivery of cholesteryl esters to 
cells mediated by the SR-BI (Krieger, 2001) as well as cholesterol efflux mediated by the cell 
surface transporter ATP binding cassette transporter G1 (ABCG1) (Wang et al., 2004). 
Finally hydrolysis of lipids of HDL is mediated by various lipases [lipoprotein lipase (LpL), 
hepatic lipase (HL), endothelial lipase (EL)] (Breckenridge et al., 1982; Brunzell and Deeb, 
2001; Ishida et al., 2003; Krauss et al., 1974). Mutations in any of these proteins may affect 
the biogenesis, maturation and the functions of HDL (Fig. 1). 
 
 
Fig. 1. Schematic representation of the pathway of the biogenesis and catabolism of HDL 
Numbers 1-11 indicate key cell membrane or plasma proteins shown to influence HDL 
levels or composition as follows: 1) apoA-I; 2) ABCA1; 3) LCAT; 4) CETP; 5) HL; 6) EL; 7) 
PLTP; 8) lipoproteins lipase; 9) SR-BI; 10) LDL receptor; 11) ABCG1. The figure is modified 
from ref. (Zannis et al., 2004b; Zannis et al., 2006b). 
3. Proteins involved in the biogenesis, remodeling and signaling of HDL 
3.1 Apolipoprotein A-I and its structure in solution and in discoidal and spherical HDL 
ApoA-I is synthesized by the liver and the intestine in humans (Williamson et al., 1992) and it 
is the major protein component of the HDL. ApoA-I along with several other proteins 
participate in the biogenesis and remodeling of HDL as well as in signaling pathways induced 
by apoA-I and HDL (Yuhanna et al., 2001; Zannis et al., 2004a). ApoA-I contains 22 or 11 
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amino acid repeats which are organized in amphipathic a-helices (Nolte and Atkinson, 1992). 
Based on the crystal structure of apoA-I in solution (Borhani et al., 1997) a belt model was 
proposed to explain the structure of apoA-I on discoidal HDL particles. In this model, two 
antiparallel molecules of apoA-I are wrapped like a belt around a discoidal bilayer containing 
160 phospholipid molecules and shields the hydrophobic fatty acid chains of the 
phospholipids. Analysis of the 93 Å spherical HDL in solution by small angle neutron 
scattering (SANS) showed that three molecules of apoA-I fold around a central lipid core that 
has 88.4 Å x 62.8 Å dimensions to form a spheroidal HDL (sHDL) particle (Wu et al., 2011). 
3.2 Interactions of ApoA-I with ABCA1 are the first step in the biogenesis of HDL  
ABCA1 is a ubiquitous protein that belongs to the ABC family of transporters and is 
expressed abundantly in the liver, macrophages, brain and various other tissues (Kielar et 
al., 2001). ABCA1 was shown to promote the efflux of cellular phospholipids and cholesterol 
to lipid free or minimally lipidated apoA-I and other apolipoproteins and amphipathic 
peptides, but it does not promote efflux to spherical HDL particles (Remaley et al., 2001; 
Wang et al., 2000). The functional interactions between apoA-I and ABCA-1 are important 
for the biogenesis of HDL. In the abscence of either apoA-I (Matsunaga et al., 1991) or 
ABCA-1 (Brunham et al., 2006) HDL is not formed. Adenovirus mediated gene transfer of 
apoA-I mutants in apoA-I-/- mice showed that deletion of the C-terminal region of apoA-I 
prevented the formation of HDL (Chroni et al., 2007). The ability of ABCA1 to promote 
cholesterol efflux from macrophages is very important for the prevention of formation of 
foam cells in the atherosclerotic lesions (Van Eck et al., 2002). Mutations resulting in 
inactivation of ABCA1 are present in patients with Tangier disease (Brunham et al., 2006). 
The deficiency is associated with very low levels of total plasma and HDL cholesterol and 
abnormal lipid deposition in various tissues (Christiansen-Weber et al., 2000; McNeish et al., 
2000). The ABCA1 deficiency in humans or experimental animals may contribute to 
accelerated atherosclerosis (Joyce et al., 2002; Singaraja et al., 2003). Inactivation of the 
ABCA1 gene in macrophages increases the susceptibility to atherosclerosis (Van Eck et al., 
2002; Van Eck et al., 2006). Specific amino acid substitutions found in the Danish general 
population were predictors of ischemic heart disease and reduced life expectancy (Frikke-
Schmidt et al., 2008). 
3.3 Interactions of lipid-bound ApoA-I with LCAT stabilize the nascent HDL  
Plasma LCAT is a 416 amino acid long enzyme that is synthesized and secreted by the liver 
and esterifies the free cholesterol of HDL and LDL. ApoA-I is a potent activator of LCAT 
(Fielding et al., 1972). Following esterification, the cholesteryl esters formed become part of 
the lipid core and the discoidal HDL is converted to mature spherical HDL (Chroni et al., 
2005a). 
Mutations in LCAT are associated with two phenotypes in humans. The familiar LCAT 
deficiency (FLD) is characterized by the inability of the mutant LCAT to esterify cholesterol 
on HDL and LDL and causes accumulation of discoidal HDL in the plasma. The fish eye 
disease (FED) is characterized by the inability of mutant LCAT to esterify cholesterol on 
HDL only. Both diseases are characterized by low HDL levels due to the inability of LCAT 
to convert the nascent immature pre-ǃ and discoidal particles to mature spherical HDL 
(Santamarina-Fojo et al., 2001).  
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3.4 Interactions of lipid-bound ApoA-I with SR-BI 
SR-BI is an 82 kDa membrane glycoprotein primarily expressed in the liver, steroidogenic 
tissues and endothelial cells but is also found in other tissues. The most important 
property of SR-BI is considered to be its ability to act as the HDL receptor (Acton et al., 
1996). SR-BI mediates both selective uptake of cholesteryl esters and other lipids from 
HDL to cells (Acton et al., 1996; Stangl et al., 1999; Thuahnai et al., 2001), as well as efflux 
of unesterified cholesterol (Gu et al., 2000). Transgenic mice expressing SR-BI in the liver 
had greatly decreased apoA-I and HDL levels as well as increased clearance of VLDL and 
LDL (Ueda et al., 1999) and were protected from atherosclerosis (Arai et al., 1999). SR-BI 
deficient mice had decreased HDL cholesterol clearance (Out et al., 2004), two fold 
increased plasma cholesterol and presence of large size abnormal apolipoprotein E (apoE) 
enriched particles that were distributed in the HDL/IDL/LDL region (Rigotti et al., 1997). 
The SR-BI deficiency in the background of LDL receptor (LDLr) deficient or apoE 
deficient mice accelerated dramatically the development of atherosclerosis (Huszar et al., 
2000; Trigatti et al., 1999). The double deficient mice for apoE and SR-BI developed 
occlusive coronary atherosclerosis, cardiac hypertrophy, myocardial infarctions, cardiac 
dysfunction and died prematurely (mean age of death ~6 weeks) (Braun et al., 2002; 
Trigatti et al., 1999). The SR-BI deficiency reduced greatly cholesteryl ester levels in the 
steroidogenic tissues that utilize HDL cholesterol for synthesis of steroid hormones (Ji et 
al., 1999). It also decreased secretion of biliary cholesterol by approximately 50% 
(Mardones et al., 2001; Rigotti et al., 1997). The SR-BI deficiency also caused defective 
maturation of oocytes and red blood cells due to accumulation of cholesterol in the 
plasma membrane of progenitor cells (Holm et al., 2002; Trigatti et al., 1999) and caused 
infertility in the female but not the male mice (Trigatti et al., 1999; Yesilaltay et al., 2006). 
Interactions of HDL with SR-BI in endothelial cells triggers signaling mechanisms 
discussed below that involve activation of endothelial nitric oxide synthase (eNOS) and 
release of NO that causes vasodilation (Mineo et al., 2003; Yuhanna et al., 2001). Human 
subjects have been identified with a P297S substitution in SR-BI. Heterozygote carriers for 
this mutation had increased HDL levels, decreased adrenal stereoidogenesis and 
dysfunctional platelets but did not develop atherosclerosis (Vergeer et al., 2011).  
A [Gly2Ser]SR-BI substitution in humans is associated with decreased follicular 
progesterone levels in Caucasian women and non viable fetuses 42 days post embryo 
transfer. Another single nucleotide polymorphism (SNP) (rs10846744) was associated with 
gestational sacs and fetal heart beats and with poor fetal viability in African-American 
women (Yates et al., 2011). 
3.5 Interactions of HDL with ABCG1 
ABCG1 is a 67 kDa protein which is a member of ABC family of half transporters. ABCG1 
is expressed in the spleen, thymus, lung, brain, endothelial cells and other tissues (Savary 
et al., 1996) and promotes cholesterol efflux from cells to HDL but not to lipid free apoA-I 
(Nakamura et al., 2004; Vaughan and Oram, 2005). The absence of ABCG1 in mice causes 
cholesterol accumulation in various tissues (Kennedy et al., 2005) and selective deletion of 
both ABCA1 and ABCG1 genes in macrophages further increases cholesterol 
accumulation and results in severe atherosclerosis (Out et al., 2008; Yvan-Charvet et al., 
2007). 
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4. Phenotypes of humans and experimental animals having apoA-I mutations 
4.1 Natural apoA-I mutations 
Several apoA-I mutations have been described in the general population that are associated 
with low plasma HDL levels. Most of the mutations affect the interaction of apoA-I with 
LCAT. Eight mutations between residues 26 and 107 and one on residue 173, have been 
associated with amyloidosis and low HDL levels (Sorci-Thomas and Thomas, 2002; Zannis 
et al., 1993) and one mutation on residue 164 is associated with increased risk for ischemic 
heart disease and reduced life expectancy (Haase et al., 2011). The in vivo interactions of 
representative naturally occurring apoA-I mutants with LCAT were studied by adenovirus-
mediated gene transfer in apoA-I deficient mice. The mutants apoA-I(Leu141Arg)Pisa and 
apoA-I(Leu159Arg)FIN produced only small amounts of HDL that formed mostly preǃ1 and 
small size ǂ4 HDL particles. The apoA-I(Arg151Cys)Paris and apoA-I(arg160Leu)Oslo formed 
discoidal HDL particles. These studies indicated that apoA-I(Leu141Arg)Pisa and apoA-
I(Leu159Arg)FIN mutation may inhibit an early step in the biogenesis of HDL due to 
insufficient esterification of the cholesterol of the preǃ1-HDL particles by the endogenous 
LCAT. The LCAT insufficiency appears to result from depletion of the plasma LCAT mass 
(Koukos et al., 2007). A remarkable finding of these studies was that all the aberrant 
phenotypes were corrected by treatment with exogenous LCAT. This indicates that LCAT 
administration could be a potential therapeutic intervention to correct low-HDL conditions 
in humans that are caused by these and other unidentified mutations (Amar et al., 2009). 
4.2 Specific bioengineered mutations in ApoA-I may cause dyslipidemia 
Four bioengineered mutations in apoA-I have been studied by adenovirus-mediated gene 
transfer in apoA-I deficient mice. Mutants apoA-I[Δ(62-78)], apoA-I [Glu110Ala/Glu111Ala] 
and apoA-I[Asp89Ala/Glu90Ala/Glu92Ala], caused combined hyperlipidemia, 
characterized by elevated plasma cholesterol and severe hypertriglyceridemia (Chroni et al., 
2004; Chroni et al., 2005b; Kateifides et al., 2011). An apoA-I[Δ89-99] mutant induced high 
plasma cholesterol, but did not affect plasma triglyceride levels (Chroni et al., 2005b).  
 
 
Fig. 2. The pathway of HDL biogenesis and functions of HDL. a-e represent sites of possible 
disruption of the HDL biogenesis pathway. Different subpopulations of HDL that have been 
generated due to these defects may have different functions. 
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The systematic study of the functions of apoA-I by adenovirus mediated gene transfer as 
well as the phenotypes of naturally occurring apoA-I mutants identified the following five 
steps where the pathway of biogenesis and/or catabolism of HDL can be disrupted: a) Lack 
of synthesis of HDL due to mutations in ABCA1 or mutations in apoA-I that affect the 
ABCA1/apoA-I interaction, b) Failure to convert efficiently the lipidated pre-ǃ HDL to 
discoidal HDL. This defect most likely results from fast catabolism of apoA-I following its 
lipidation by ABCA1, c) Accumulation of discoidal HDL. This phenotype has been 
generated by the mutations in the 149-160 region of apoA-I that affect LCAT activation, d) 
Accumulation of discoidal HDL and induction of hypercholesterolemia. This condition has 
been observed in the case of the apoA-I[Δ(89-99)] mutant, e) Induction of 
hypertriglyceridemia. This defect has been observed in the case of apoA-I[Δ(62-78)], apoA-
I[Glu110Ala/Glu111Ala] and apoA-I[Asp89Ala/Glu90Ala/Glu92Ala] mutants (Fig. 2). 
5. Physiological functions of ApoA-I and HDL that may be relevant to its 
atheroprotective properties 
5.1 Cell signaling pathways mediated by HDL and apoA-I 
Various studies have shown that increased HDL levels are associated with greater 
vasodilator effects in humans and this effect is impaired in patients with coronary heart 
disease (CHD) (Li et al., 2000; Zeiher et al., 1994). Treatment with HDL increased eNOS 
protein levels in cultured human aortic endothelial cells (HAECs) (Ramet et al., 2003). Other 
studies in endothelial cells and Chinese hamster ovary (CHO) cells that express SR-BI, 
showed that SR-BI-HDL interactions lead to the phosphorylation and activation of eNOS. 
The HDL-induced eNOS activation occurs in the caveolae. The HDL-mediated NO-
dependent relaxation is lost in aortic rings of SR-BI-/- mice (Yuhanna et al., 2001). 
Experiments in cultures of endothelial cells and COS M6 cells transfected with eNOS and 
SR-BI showed that interaction of HDL with SR-BI triggered signalling mechanisms which 
led to phosphorylation of eNOS at Ser1179 and increased its activity. On the other hand 
phosphorylation of Thr 497 of eNOS attenuated its activity. The signalling cascade initially 
involves the nonreceptor tyrosine kinase Src which phosphorylated PI3 kinase (PI3K). 
Inhibition of Src by specific inhibitors prevented eNOS phosphorylation. PI3K activation led 
to phosphorylation of Akt and mitogen-activated protein kinase (MAPK) which 
independently phosphorylated eNOS. Inhibitors of MAPK did not affect HDL-mediated Akt 
activation and a dominant negative Akt did not affect HDL-mediated MAPK activation and 
eNOS phosphorylation (Mineo et al., 2003) (figure 3A). 
The mechanism of the SR-BI mediated activation of eNOS was studied in detail (Assanasen 
et al., 2005). HDL and cholesterol-free reconstituted HDL (rHDL) particles containing apoA-
I and phosphatidylocholine (Lp2A-I) as well as cyclodextrin stimulated eNOS activity 
whereas rHDL particles that contain cholesterol did not. Blocking of cholesterol efflux with 
a monoclonal antibody to SR-BI abolished the activation of eNOS. Experiments were 
performed using SR-BII, a splice variant of SR-BI as well as a SR-BI mutant that lacks the 
carboxyterminal amino acid 509 [SR-BI(Δ509)] and chimeric receptors where the 
transmembrane and the C-terminal domains of SR-BI were replaced by the corresponding 
domains of CD36. These studies established that the C-terminal cytoplasmic PDZ-
interacting domain and the C-terminal transmembrane domain of SR-BI were both required 
for eNOS activation (Assanasen et al., 2005). The cytoplasmic PDZK1 interacting domain of 
SR-BI binds adaptor proteins such as PDZK1 that may participate in cell signalling (Kocher 
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et al., 2003). A photoactive derivative of cholesterol binds in the transmembrane region of 
SR-BI indicating that this region serves as a cholesterol sensor on the plasma membrane 
(Assanasen et al., 2005). HDL and lysophospholipids that are components of HDL including 
sphingosylphosphorylcholine, sphingosine-1-phospate (S1P) and lysosulphatide cause 
eNOS dependent relaxation of mouse aortic rings via intracellular Ca2+ mobilization and 
eNOS phosphorylation mediated by Akt (Nofer et al., 2004). Another study however, 
indicated that interactions of HDL with SR-BI stimulate eNOS by increasing intracellular 
ceramide levels without affecting intracellular calcium levels and Akt phosphorylation (Li et 
al., 2002). The proposed role of HDL-associated estradiol in the stimulation of eNOS activity 
is unclear (Gong et al., 2003). 5’ AMP-activated protein kinase (AMPK) may also play a role 
in the HDL-mediated phosphorylation of eNOS at multiple sites (Ser116, Ser635, and 
Ser1179) (Drew et al., 2004). It was suggested that activation by AMPK may involve physical 
interactions between the apoA-I component of HDL and eNOS. Such interactions may be 
possible following SR-BI mediated endocytosis of HDL (Silver et al., 2001). HDL also 
affected the signaling in endothelial cells by the bone morphogenetic protein 4 (BMP4) and 
increased expression of the activin-like kinase receptor 1 and 2 (Yao et al., 2008). This 
resulted in increased expression of vascular endothelial growth factor (VEGF) and matrix 
gla protein (MGP). VEGF promotes endothelial cell survival and MGP prevents vascular 
calcification and thus contribute to the maintenance, the integrity and the preservation of 
the functions of the endothelium (Yao et al., 2008). 
 
 
Fig. 3. A) Schematic representation of SR-BI signaling that can lead to vasodilation, cell 
migration and inhibition of inflammation and apoptosis. B) Schematic representation of 
PKC-dependent SR-BI-dependent signalling pathway that promote cell proliferation (Drew 
et al., 2004; Grewal et al., 2003; Kimura et al., 2003; Mineo et al., 2003). 
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5.2 Effect of HDL and apoA-I on inflammation 
An initial step in the pathogenesis of atherosclerosis is the association of the monocytes to 
adhesion molecules of the endothelial cells that facilitates their entry in the sub-endothelial 
space (Zannis et al., 2004b). Induction of adhesion molecules is promoted by pro-
inflammatory stimuli (Cybulsky and Gimbrone, Jr., 1991). Recruitment and migration of 
monocytes into sub-endothelial space is promoted by the monocyte chemoattractant factor 
(MCP-1) as well as by oxidized LDL (Peters and Charo, 2001). HDL has anti-oxidant 
properties and can prevent the oxidation of LDL (Navab et al., 2000a; Navab et al., 2000b). 
Interactions of HDL or apoA-I with cells of the vascular wall were shown to prevent the 
expression of pro-inflammatory cytokines and chemokines that induce the expression of 
adhesion molecules (Bursill et al., 2010; Cockerill et al., 1995; Nobecourt et al., 2010). The 
anti-inflammatory functions of HDL were manifested in several ways. HDL binds via its 
apoA-I moiety to progranulin produced by macrophages. This prevents conversion of 
progranulin to inflammatory granulins which were shown to induce expression of tumor 
necrosis factor ǂ (TNFǂ) and interleukin (IL) 1ǃ in monocyte macrophages (Okura et al., 
2010). HDL and rHDL were shown to inhibit the cytokine induced expression of vascular 
cell adhesion molecule-1 (VCAM-1) and inter-cellular adhesion molecule-1 (ICAM-1) by 
endothelial cells (Cockerill et al., 1995). In addition, HDL promoted the expression of anti-
inflammatory cytokines in endothelial cells. Thus treatment of endothelial cells (HUVEC) 
with HDL and lysosphingolipids present in HDL, increased the expression of TGF-ǃ2 
through mechanisms that involve the activation of Akt and extracellular signal regulated 
kinases (ERK) 1/2. Consistent with cell culture studies, the expression of transforming 
growth factor-ǃ2 (TGF-ǃ2) and the phosphorylation of ERK1/2, Akt and Smad2/3 were 
increased in apoA-I transgenic mice and diminished in apoA-I deficient mice (Norata et al., 
2005). In vivo studies also showed that infusion of rHDL inhibited the pro-oxidant and pro-
inflammatory events that occurred following implantation of non occlusive periarteral 
collars in rabbits that induce acute arterial inflammation. In these studies the rHDL 
inhibited neutrofil infiltration, production of reactive oxygen species (ROS) and the 
expression of VCAM-1, ICAM-1, MCP-1 and E-selectin (Nicholls et al., 2005b). The carotid 
vascular inflammation and neutrofil infiltration could be inhibited by rHDL containing 
normal apoA-I but not by apoA-I obtained from diabetic patients (Nobecourt et al., 2010). 
The beneficial effects of rHDL containing apoA-I in vivo and in cell cultures could be 
duplicated using synthetic apoA-I mimetics such as 5A, L37pA and D37pA (Gomaraschi et 
al., 2008; Tabet et al., 2010). The 5A/PLPC complexes reduced the vascular inflammation 
that is associated with collar insertion in a rabbit model by reducing the ICAM-1 and 
VCAM-1 expression, the infiltration of neutrofils and the Nox4 activity. In cultures of 
human carotid endothelial cells (HCEC) 5A/PLPC and rHDL containing apoA-I inhibited 
the TNF-ǂ induced VCAM-1 and ICAM-1 expression as well as the activation of  
nuclear factor κB (NF-κΒ) pathway and these effects were abolished by ABCA1 silencing  
(Tabet et al., 2010). Complexes of L37pA or D37pA with ǃ-oleoyl-Ǆ-palmitoyl-L-ǂ-
phosphatidylcholine reduced the postischemic cardiac contractile dysfunction in a rat heart 
model of ischemia/reperfusion. They also reduced TNF-ǂ levels and increased prostacyclin 
levels in the perfusate and inhibited the TNF-ǂ mediated VCAM-1 expression in endothelial 
cell cultures (Gomaraschi et al., 2008). In monocyte and endothelial cell cultures HDL also 
suppressed expression of chemokines CCL2, CCL5 and CX3CL1 and chemokine receptors 
CCR2, CCR5 and CX3CR1 (Bursill et al., 2010). This effect was mediated by inhibition of Iκ-
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Bǂ phosphorylation and NF-κB(p65) expression and in some cases by peroxisome 
proliferator-activated receptor Ǆ (PPARǄ) activation. Consistent with cell culture studies, in 
vivo infusion of apoA-I in cholesterol fed apoE deficient mice reduced expression of 
chemokines and chemokine receptors (Bursill et al., 2010). HDL and its protein moiety 
apoA-I have been shown to inhibit the expression of CD11b of human monocytes that is 
induced by phorbol myristate acetate (PMA) and promote cell adhesion. Inhibition of the 
ABCA1-mediated and to a lesser extent SR-BI mediated cholesterol efflux by monoclonal 
antibodies attenuated the inhibitory effect of apoA-I and HDL respectively. Expression of 
CD11b was also affected by depletion of the membrane cholesterol by treatment of the cells 
with cyclodextrin (Murphy et al., 2008), pointing out to a potential role of cholesterol efflux 
in the inhibition of inflammation. Consistent with the ex vivo studies infusion of rHDL in 
patients with type 2 diabetes mellitus, reduced the expression of CD11b of the peripheral 
monocytes and reduced the adhesion of the patients’ neutrophils to a fibrinogen matrix. 
Plasma HDL isolated 4 to 72 hours post rHDL infusion suppressed the expression of 
VCAM-1 in cultures of HAECs and had increased ability to promote cholesterol efflux from 
THP-1 macrophages (Patel et al., 2009). In cultures of smooth muscle cells, HDL 
downregulated the NADPH-oxidase mediated generation of reactive oxygen species (ROS) 
and inhibited production of MCP-1. The inhibitory effect was attenuated by antagonists of 
S1P1 and S1P3 receptors. The data showed that free S1P or S3P alone or as components of 
HDL could attenuate production of MCP-1. Consistent with these findings, MCP-1 
production and ROS generation in the aortas of S1P3-/- receptor and SR-BI-/- mice were not 
affected by treatment with HDL, S1P and sphingosylphosphorylcholine (SPC) (Tolle et al., 
2008). ApoA-I induced the expression of the adhesion molecule CD31, and changed the 
morphology and size distribution of lineage negative bone marrow cells. The treatment also 
increased the ability of the cells to bind to fibronectin and to cultured endothelial cells. 
Deletion of the C-terminal helix 10 of apoA-I abolished the effects of apoA-I on bone 
marrow cells (Mythreye et al., 2008). 
5.3 Effect of HDL and apoA-I on endothelial cell apoptosis 
Exposure of endothelial cells to inflammatory stimuli may disturb the endothelial 
monolayer integrity (Dimmeler et al., 2002). Numerous factors that promote endothelial 
apoptosis have been described and include OxLDL (Li et al., 1998), TNF-a (Dimmeler et al., 
1999), homocysteine (Welch and Loscalzo, 1998), and angiotensin II (Strawn and Ferrario, 
2002). HDL also can reverse the TNF-a induced and growth deprivation induced endothelial 
cell apoptosis (Nofer et al., 2001; Sugano et al., 2000). OxLDL increased intracellular calcium 
and resulted in apoptosis that could be inhibited by HDL and apoA-I (Suc et al., 1997). 
ApoA-I interacts with ABCA1 and F1-ATPase (Chroni et al., 2003; Vantourout et al., 2010), 
whereas HDL interacts with SR-BI and ABCG1 (Liadaki et al., 2000; Wang et al., 2004) 
respectively and the sphingolipid components of HDL interact with the S1P receptors 
(Kimura et al., 2003; Okajima et al., 2009). HDL protected endothelial cells from apoptosis 
induced by oxLDL by preventing the generation of intracellular ROS. The anti-apoptotic 
activity was highest for HDL3 and diminished as the size of HDL increased. It was 
suggested that approximately 70% of the anti-apoptotic activity of HDL was attributed to 
apoA-I which has the capacity to accept through its methionine residues the phospholipid 
hydroperoxides (PLOOH) of oxLDL (de Souza et al., 2010). The anti-apoptotic functions of 
small size HDL3 was reduced by 35% in subjects with metabolic syndrome and this 
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reduction was correlated with the clinical phenotype of the human subjects. Compared to 
normal HDL the HDL3 fractions of the diabetic subjects had increased total triglyceride 
levels and decreased cholesteryl esters/triglycerides ratio suggesting that the lipid core of 
HDL3 was enriched with triglycerides (de Souza et al., 2008). HDL3 also inhibited apoptotic 
cell death induced by oxLDL and preserved lysosomal integrity of an osteoblastic cell line 
(Brodeur et al., 2008). The anti-apoptotic effects were attributed to the increased expression 
of SR-BI that is mediated by HDL3, combined with the ability of HDL to compete for the 
binding of oxLDL to osteoblasts as well as increased selective uptake of the cholesterol of 
the oxLDL by these cells (Brodeur et al., 2008). 
Interactions of apoA-I with cell surface F1-ATPase inhibited apoptosis of HUVEC and 
stimulated cell proliferation (Radojkovic et al., 2009). In the absence of apoA-I, specific 
inhibitors for F1-ATPase (IF1-H49K) and angiostatin or specific antibodies to F1-ATPase 
promoted apoptosis and inhibited cell proliferation. In the presence of apoA-I, F1-ATPase 
inhibitors and antibodies diminished its anti-apoptotic and anti-proliferative effects. Down-
regulation of the ABCA1 by siRNA did not affect the anti-apoptotic and proliferative 
functions of apoA-I whereas inhibition of SR-BI by a specific antibody diminished the anti-
apoptotic and proliferative functions of HDL3 (Radojkovic et al., 2009). The findings suggest 
that interactions of lipid free apoA-I with F1-ATPase and of HDL with SR-BI contribute to 
their anti-apoptotic and proliferative effects on endothelial cells. The antiapoptotic effects of 
HDL on endothelial cells could be mimicked by the lysosphingolipid components of HDL 
(Nofer et al., 2001). The SR-BI mediated signalling that leads to activation of eNOS, also 
promotes cell growth and migration and protects cells from apoptosis (Mineo et al., 2006; 
Noor et al., 2007). Activation of eNOS required its localization in the caveolae, where 
caveolin SR-BI and CD36 are also found (Uittenbogaard et al., 2000). It has been proposed 
that oxLDL acting through CD36 depletes the cholesterol content of caveolae and leads to 
eNOS redistribution to intracellular sites thus resulting in decreased eNOS activity (Blair et 
al., 1999; Uittenbogaard et al., 2000). HDL acting through SR-BI maintains the concentration 
of caveolae-associated cholesterol, inhibits the actions of oxLDL and maintains eNOS in the 
caveolae (Uittenbogaard et al., 2000). This interpretation implies that strong interactions 
between eNOS and caveolin-1 (Cav-1) stimulate eNOS activity. Other studies provided the 
opposite mechanism of modulation of eNOS activity by interactions of eNOS with Cav-1 
(Terasaka et al., 2010). It was shown that these interactions were enhanced by loading cells 
with cholesterol or oxysterols and decreased by cholesterol depletion in endothelial cells as 
a result of ABCG1-mediated cholesterol efflux. Studies in murine lung endothelial cells 
(MLEC) also showed that HDL could reverse the inhibition of eNOS activity caused by 
cholesterol loading in the normal but not the Cav-1 deficient cells (Terasaka et al., 2010). It 
was proposed that diminished interactions between eNOS and Cav-1 caused by ABCG1-
mediated efflux stimulated eNOS activity. It has been shown that oxidized phospholipids 
uncouple eNOS activity and lead to the generation of oxygen radicals which induces the 
expression of sterol regulatory element binding protein (SREBP) and IL-8 (Gharavi et al., 
2006; Yeh et al., 2004). ApoA-I mimetic peptides also prevent LDL from uncoupling eNOS 
activity to favour O2.- anion production as opposed to normal production of NO (Ou et al., 
2003). Finally it has been shown that SR-BI via a highly conserved redox motif CXXS 
between residues 323-326 can promote a ligant independent apoptosis via a caspase 8 
pathway and this effect could be reversed by HDL and eNOS (Li et al., 2005). It was 
proposed that at low HDL levels oxitative stress causes relocation of eNOS away from the 
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caveolae and this results in SR-BI induced apoptosis (Li et al., 2005). The picture that 
emerges from these studies is that HDL promotes survival and migration of endothelial cells 
by signalling mechanisms that originate from the interactions of HDL with SR-BI, the 
interactions of S1P with S1P1 and S1P3 receptors and the interactions of lipid-free apoA-I 
with F1-ATPase. 
5.4 Effect of HDL on endothelial cell proliferation and migration 
Damage of the endothelium is associated with vascular disease which can be blunted by re-
endothelialization (Werner et al., 2003). HDL promoted proliferation of HUVEC via 
mechanisms that increased intracellular Ca2+ and upregulated the production of 
prostacyclin (Tamagaki et al., 1996). HDL also promoted endothelial cell migration 
(Murugesan et al., 1994). Migration was promoted by signalling cascades mediated by 
interaction of S1P with S1P1 and S1P3 receptors that led to the activation of PI3 kinase, 
p38MAP kinase and Rho kinases (Kimura et al., 2003). Other studies showed that HDL can 
activate the MAPK pathway either through processes that involve protein kinase C (PKC), 
Raf-1, MEK and ERK1/2 or PKC independent pathways. This latter pathway leads to the 
activation of Ras and can be inhibited by pertussis toxin and neutralizing antibodies against 
SR-BI (Grewal et al., 2003). The data suggest that interactions of HDL with SR-BI activate 
Ras in a PKC independent manner and this leads to subsequent activation of MAPK 
signalling cascade (Grewal et al., 2003) (Fig.3B). Another beneficial effect of HDL is its 
capacity to promote capillary tube formation in vitro. This function is pertussis toxin 
sensitive and requires p44/42MAP kinase which is downstream of Ras (Miura et al., 2003). 
Other studies showed that interaction of SR-BI with HDL or rHDL, activated Src kinases 
and Rac GTPases and stimulated endothelial cell migration. In vivo experiments have also 
shown that re-endothelialization of carotid artery following injury is promoted by apoA-I 
expression and is inhibited in apoA-I deficient in mice (Seetharam et al., 2006). 
5.5 Effect of HDL on thrombosis 
Increased HDL cholesterol levels are associated with decreased risk of venous thrombosis 
(Doggen et al., 2004). In contrast low HDL levels are associated with increased risk of 
venous thrombosis (Deguchi et al., 2005). The ability of HDL to inhibit endothelial cell 
apoptosis (Dimmeler et al., 2002; Mineo et al., 2006) prevents vessel denudation and 
formation of microparticles that may contribute to thrombosis (Durand et al., 2004). It has 
been shown that thrombogenic membrane microparticles that may originate from apoptotic 
endothelial cells are increased in the plasma of patients with acute coronary syndrome 
(ACS) (Mallat et al., 2000). Infusion of rHDL in volunteers that received low levels of 
endotoxin limited the prothrombotic and procoagulant effect of endotoxin (Pajkrt et al., 
1997). Furthermore infusion of apoA-IMILANO in a rat model of acute arterial thrombosis 
increased the time of thrombus formation and decreased the weight of the thrombus (Li et 
al., 1999). HDL may affect thrombosis via a variety of mechanisms: Early studies showed 
that HDL causes increased synthesis of prostacyclin in cultured endothelial cells (Fleisher et 
al., 1983; Tamagaki et al., 1996). Prostacyclin in combination with NO promote smooth 
muscle cells relaxation, inhibit platelet activation and local smooth muscle cell proliferation 
(Vane and Botting, 1995). It has been reported that HDL3 induced expression of 
cyclooxygenase-2 (Cox-2) by smooth muscle cells and promoted release of prostacyclin 
(PGI2) via a signalling pathway that involves p38MAP kinase and c-Jun N terminal kinase 
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(JNK-1) (Escudero et al., 2003; Vinals et al., 1997). PGI2 synthesis was enhanced by 
HMGCoA reductase inhibitors (Martinez-Gonzalez et al., 2004). It has been shown that there 
is a positive correlation between plasma HDL levels and anticoagulant response to activated 
protein C (APC)/protein S in vitro (Griffin et al., 1999) and negative correlation with the 
plasma thrombin activation markers such as prothrombin fragments F1.2 and D-dimer 
(MacCallum et al., 2000). APC inactivates, by proteolysis, factors Va and VIIIa in plasma and 
thus it can downregulate thrombin formation. Administration of HDL to cholesterol-fed 
rabbits also increased endothelial cell thrombomodulin levels, promoted generation of APC 
and inhibited formation of thrombin (Nicholls et al., 2005a). Glucosylceramide and 
glycosphingolipids which are present in HDL are lipid cofactors for the anticoagulant 
activity of APC and in a significant number of patients with venous thrombosis the levels of 
glucosylceramides are low (Deguchi et al., 2002; Deguchi et al., 2001). Shpingosine, another 
molecule present in HDL, has been shown to inhibit prothrombin activation on platelets’ 
surface by disrupting procoagulant interactions between factors Xa and Va (Deguchi et al., 
2004). HDL also downregulated expression of plasminogen activator inhibitor-1 (PAI-1) and 
upregulated tissue plasminogen activator (t-PA) in endothelial cell cultures (Eren et al., 
2002). Transgenic mice expressing the human PAI-1 developed age-dependent coronary 
arterial thrombosis (Eren et al., 2002). In contrast oxidized HDL3 induced the expression of 
PAI-1 in endothelial cells through signalling mechanisms that involve activation of ERK1/2 
and p38MAPK and mRNA stabilization (Norata et al., 2004).  
5.6 Effects of HDL on diabetes mellitus 
In vivo and in vitro studies have provided evidence that HDL may have beneficial effects on 
glucose metabolism (Koseki et al., 2009; Rutti et al., 2009). Ex vivo studies showed that HDL 
and delipidated apoA-I or S1P decreased IL-1ǃ and glucose-mediated apoptosis and thus 
increased the survival of human and murine islets. HDL treatment down-regulated the 
expression of iNOS and its downstream target Fas which is pro-apoptotic and up-regulated 
the expression of FLICE-like inhibitory protein (FLIP) which is anti-apoptotic (Rutti et al., 
2009). HDL also reversed the toxic effects of oxidized LDL on beta cells that are associated 
with apoptosis and cJNK mediated transcriptional repression of the insulin gene caused 
cJNK mediated (Abderrahmani et al., 2007).  
Oral glucose tolerance test in a limited number of patients with Tangier disease (that lack or 
have dysfunctional ABCA1) showed that they had glucose intolerance as compared to 
controls (Koseki et al., 2009), thus implicating ABCA1, apoA-I and HDL in glucose 
metabolism. Cell culture studies using primary pancreatic islets cells and a pancreatic ǃ-cell 
line (Min6), showed that lipid free apoA-I or apoA-II or reconstituted HDL increased insulin 
secretion up to 5-fold in a Ca2+ dependant manner (Fryirs et al., 2010). The free 
apolipoproteins also increased insulin mRNA levels. HDL mediated insulin secretion has 
also been observed in cultures of mouse pancreatic ǃ-cells (MIN6N8) (Drew et al., 2009). The 
increase in insulin secretion mediated by lipid-free apoproteins and rHDL required the 
functions of ABCA1 and SRBI or ABCG1 respectively. These functions may be different 
from those involved in cholesterol efflux. For high glucose concentrations enhanced insulin 
secretion required the action of KATP channel and glucose catabolism in the pancreatic cell, 
but this did not occur for low glucose concentrations (Fryirs et al., 2010).  
Further insight on the role of ABCA1 in diabetes was obtained by studies in mice with 
selective deficiency of ABCA1 in the pancreas (ABCA1-P/-P). These mice accumulated 
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cholesterol in their islets and were characterized by impaired acute phase insulin secretion 
and glucose intolerance. The ABCA1-P/-P mice exhibited normal insulin sensitivity indicating 
normal response of the peripheral tissues to insulin. The impairment in insulin secretion 
was verified in cell culture experiments using islets isolated from the ABCA1-P/-P mice. In 
contrast, whole ABCA1 deficient mice had normal glucose tolerance and displayed only 
small impairment in the islet function and did not accumulate significant amount of 
cholesterol in the islets (Brunham et al., 2007). Pancreatic islets isolated from apoE deficient 
mice had increased cholesterol content and reduced insulin secretion as compared to islets 
obtained from WT mice. The reduced insulin secretion in the pancreatic islets or cultures of 
ǃ-cells could be restored by depletion of the cellular cholesterol using mevastatin or methyl-
ǃ-cyclodextrin (MǃCD) (Hao et al., 2007). Experiments in cell lines of pancreatic ǃ-cell origin 
indicated that cholesterol loading or cholesterol depletion affect the activity of glucokinase 
(GK) which is known to regulate insulin secretion (Rizzo and Piston, 2003). The experiments 
showed that under normal cholesterol levels GK is associated with a dimeric form of nNOS on 
insulin containing granules in the cytoplasm and is inactive (Rizzo and Piston, 2003). Increase 
in plasma cholesterol enhanced dimerization of nNOS and its association with GK whereas 
reduction in the cholesterol levels or increase in the extracellular glucose levels promoted 
monomerization of nNOS and release of active GK in the cytoplasm (Hao et al., 2007). The role 
of the increase in the cholesterol content of ǃ-cells in insulin secretion was tested in transgenic 
mice expressing SREBP-2 in ǃ-cells under the control of insulin promoter. These mice had 
normal plasma cholesterol levels but developed severe diabetes characterized by 5-fold 
increase in gluco-hemoglobin and defects in glucose and potassium-stimulated insulin 
secretion and were characterized by glucose intolerance. The islets were fewer, smaller and 
deformed and had increased levels of total and esterified cholesterol (Ishikawa et al., 2008). It 
was proposed that the loss of ǃ-cell mass could be related to the down regulation of genes such 
as PDX-1 and BETA2 that are involved in ǃ-cell differentiation.  
A recent comprehensive study has measured the properties of HDL isolated from patients 
with type 2 diabetes mellitus and their functions on endothelial cells in vitro and in vivo. 
HDL isolated from patients with low HDL and type 2 diabetes mellitus contained increased 
levels of lipid peroxides and increased myeloperoxidase activity. In endothelial cell cultures 
diabetic HDL had reduced production of NO and increased NADPH oxidase activity that 
resulted in increased oxidant stress. Diabetic HDL had diminished endothelium dependent 
relaxation of aortic rings and endothelial progenitor cells obtained from diabetic subjects 
had diminished capacity to promote reendothelialization in vivo. A remarkable finding in 
this study was that extended release niacin treatment of the diabetic patients restored the 
properties and functions of HDL. The HDL obtained after treatment had normal levels of 
peroxides and normal myeloperoxidase (MPO) activity. Studies with endothelial cultures 
showed that following treatment of the diabetic patients their HDL could induce normal NO 
production and NADPH oxidase activity and could promote normal relaxation of aortic 
rings. Endothelial progenitor cells obtained from diabetic patients following niacin 
treatment had normal ability to promote reendothelialization in vivo (Sorrentino et al., 
2010). In another study intravenous infusion of rHDL (80 mg/kg over 4 hours) in type 2 
diabetic human subjects decreased plasma glucose level, increased plasma insulin level and 
increased ǃ-cell functions as compared to patients receiving placebo (Drew et al., 2009). 
HDL and apoA-I increased glucose uptake of primary human skeletal muscle cultures 
established from patients with type 2 diabetes mellitus. HDL induced glucose uptake and 
fatty acid oxidation and increased AMPKǂ2 activity and phosphorylation. These effects 
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were modulated through a Ca2+ dependent pathway. Subsequent in vitro and in vivo studies 
showed that rHDL inhibited lipolysis in 3T3-L1 adipocytes partially via activation of AMPK 
pathway (Drew et al., 2011). Infusion of rHDL also inhibited fasting induced lipolysis and fatty 
acid oxidation but increased the circulating non essential fatty acids possibly due to the action 
of phospholipase on the rHDL phospholipids (Drew et al., 2011). The HDL dependent glucose 
uptake by the skeletal muscle cells was abrogated by inhibition of ABCA1 with a blocking 
antibody suggesting that ABCA1 functions not related to cholesterol efflux, may contribute to 
the increased glucose uptake and ǃ-oxidation by skeletal muscle cells obtained from patients 
with type 2 diabetic mellitus (Drew et al., 2011). The effect of apoA-I on glucose metabolism 
was also studied in C2C12 myocytes and apoA-I deficient mice. Consistent with the studies 
with primary human skeletal muscle cultures, apoA-I stimulated AMPK and acetyl-CoA 
carboxylase (ACC) phosphorylation and glucose uptake and endocytosis into C2C12 cells. The 
apoA-I deficient mice had increased fat content decreased glucose tolerance and increased 
expression of gluconeogenic enzymes in the liver and decreased AMPK-dependent 
phosphorylation in skeletal muscle and the liver (Han et al., 2007).  
5.7 Role of apoA-I and HDL in atheroprotection 
Atherosclerosis is associated with lipid and lipoprotein abnormalities (Zannis et al., 2004b). 
Low HDL levels (Gordon et al., 1989) and decreased concentration of the largest size HDL 
subpopulations (Asztalos et al., 2004) are associated with increased risk of CAD. The anti-
atherogenic functions of HDL and apoA-I have been, to a large extent, attributed to the 
beneficial effects that HDL exerts on cells of the arterial wall as well as their ability to 
promote efflux from macrophages and other cells of the arterial wall via ABCA1, ABCG1 
and SR-BI (Wang et al., 2007). Hepatic overexpression of apoA-I gene in the background of 
apoE or LDLr deficient mice reduced the atherosclerosis burden of these mice following an 
atherogenic diet (Tangirala et al., 1999). These findings demonstrate the importance of 
apoA-I and HDL for atheroprotection. In contrast, double deficient mice for apoA-I and the 
LDLr fed an atherogenic diet developed atherosclerosis and had increased concentration of 
circulating auto-anibodies, increased population of T, B, dendritic cells and macrophages, as 
well as increased T cell proliferation and activation. The abnormal phenotype was corrected 
by adenovirus mediated gene expression of apoA-I (Wilhelm et al., 2010). Similarly apoA-I 
transgenic rabbits were resistant to diet induced atherosclerosis (Duverger et al., 1996).  
Two clinical trials showed that intravenous administration of 15 mg/kg of apoA-
IMILANO/phospholipid complexes in five weekly doses in patients with acute coronary 
syndrome resulted in significant regression of atherosclerosis as it was shown by intravascular 
ultrasound (Nicholls et al., 2006; Nissen et al., 2003). The epidemiological studies (Gordon et 
al., 1989), combined with studies of experimental animals (Duverger et al., 1996; Tangirala et 
al., 1999) and clinical intervention studies (Barter et al., 2007; Sorrentino et al., 2010) highlight 
the importance of increased HDL levels for atheroprotection. However, human subjects have 
been identified with high HDL levels and CAD (Ansell et al., 2003). In addition, increased 
HDL levels in humans treated with the CETP inhibitor torcetrapib, increased cardiovascular, 
and non-cardiovascular deaths (Barter et al., 2007). These findings suggest that high HDL 
levels are not always synonymous with atheroprotection. The concept that emerges from all 
the studies is that the most important factor for atheroprotection is the functionality of HDL. 
Understanding of the structure-function and the cell signaling associated with HDL and apoA-
I will provide molecular explanations for their beneficial effects for atherosclerosis and other 
human diseases and apoA-I. 
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6. Conclusion  
Numerous prospective epidemiological studies have established an inverse correlation 
between HDL cholesterol levels and the risk for CAD. However, the discovery of human 
subjects with high HDL cholesterol levels and CAD, combined with clinical intervention 
studies designed to raise HDL levels and studies of animal models, led to the realization 
that high levels of HDL cholesterol alone are not sufficient to prevent atherosclerosis. HDL 
via its protein and/or lipid components participates in numerous interactions with the 
endothelium, other cells of the vascular wall, as well as with ǃ pancreatic cells, and has a 
protective effect against atherothrombosis and other diseases. The key proteins that 
participate in the biogenesis, remodeling and signaling of HDL are of great importance for 
the functionality of HDL. Mutations in apoA-I, ABCA1 and LCAT affect the biogenesis of 
HDL and either prevent formation of HDL or generate aberrant HDL subpopulations which 
may have altered functions. The ability of HDL to inhibit the oxidation of LDL, prevents the 
induction of pro-inflammatory and pro-apoptotic pathways that are detrimental to the 
endothelium. HDL interacts directly with the endothelial cells via SR-BI and the ABCG1. 
These interactions lead to NO release and vasodilatation, promote reendothelialization and 
suppress expression of adhesion molecules on endothelial cells in response to pro-
inflammatory cytokines. As a result of these and other interactions of the sphingolipid 
components of HDL with S1P receptors, HDL protects from apoptosis and inflammation 
and promotes endothelial cell growth and migration. Understanding the complexity and the 
functions of HDL may facilitate in the near future the development of new HDL-based 
therapies to prevent or treat atherosclerosis and other human diseases. 
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